Home  »  Companies   »  A Lesson to Learn: Intra-Cellular Therapies Inc. (...

A Lesson to Learn: Intra-Cellular Therapies Inc. (ITCI)

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) went down by -3.18% from its latest closing price compared to the recent 1-year high of $66.00. The company’s stock price has collected 2.56% of gains in the last five trading sessions. The Wall Street Journal reported on 12/20/21 that Pandemic Trades Roar Back: What to Watch in the Stock Market Today

Is It Worth Investing in Intra-Cellular Therapies Inc. (NASDAQ :ITCI) Right Now?

Plus, the 36-month beta value for ITCI is at 1.16.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


ITCI currently public float of 92.23M and currently shorts hold a 4.40% ratio of that float. Today, the average trading volume of ITCI was 707.28K shares.

ITCI’s Market Performance

ITCI stocks went up by 2.56% for the week, with a monthly jump of 14.60% and a quarterly performance of 3.81%, while its annual performance rate touched 21.85%. The volatility ratio for the week stands at 4.24% while the volatility levels for the past 30 days are set at 5.24% for Intra-Cellular Therapies Inc. The simple moving average for the period of the last 20 days is 2.86% for ITCI stocks with a simple moving average of -4.83% for the last 200 days.

Analysts’ Opinion of ITCI

Many brokerage firms have already submitted their reports for ITCI stocks, with Goldman repeating the rating for ITCI by listing it as a “Neutral.” The predicted price for ITCI in the upcoming period, according to Goldman is $49 based on the research report published on August 22nd of the current year 2022.

Mizuho, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $74. The rating they have provided for ITCI stocks is “Buy” according to the report published on July 07th, 2022.

UBS gave a rating of “Buy” to ITCI, setting the target price at $75 in the report published on June 14th of the current year.

ITCI Trading at 6.82% from the 50-Day Moving Average

After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.44% of loss for the given period.

Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 4.24%, as shares surge +11.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.07% upper at present.

During the last 5 trading sessions, ITCI rose by +2.56%, which changed the moving average for the period of 200-days by +0.14% in comparison to the 20-day moving average, which settled at $50.03. In addition, Intra-Cellular Therapies Inc. saw -2.20% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ITCI starting from MARCUS JOEL S, who sale 10,000 shares at the price of $52.30 back on Nov 07. After this action, MARCUS JOEL S now owns 34,233 shares of Intra-Cellular Therapies Inc., valued at $523,023 using the latest closing price.

Hineline Lawrence J., the SVP of Finance CFO of Intra-Cellular Therapies Inc., sale 65,164 shares at $45.63 during a trade that took place back on Sep 21, which means that Hineline Lawrence J. is holding 0 shares at $2,973,406 based on the most recent closing price.

Stock Fundamentals for ITCI

Equity return is now at value -45.50, with -40.40 for asset returns.

Is Twilio Inc. (TWLO) a Keeper?

Twilio Inc. (NYSE:TWLO) went down by -5.24% from its latest closing price compared to the recent 1-year high of $289.00. The company’s stock price has